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Abstract
 
Members of the suppressor of cytokine signaling (SOCS) family were discovered as negative
regulators of cytokine signaling by inhibition of the Janus kinase–signal transducer and activator
of transcription (Jak-STAT) pathway. Among them, cytokine-induced Src homology 2 (SH2)
protein (CIS) was found to inhibit the interleukin 3– and erythropietin-mediated STAT5 sig-
naling pathway. However, involvement of SOCS proteins in other signaling pathways is still
unknown. This study shows that the expression of CIS is selectively induced in T cells after T
cell receptor (TCR) stimulation. In transgenic mice, with selective expression of CIS in CD4 T
cells, elevated CIS strongly promotes TCR-mediated proliferation and cytokine production in
vitro, and superantigen-induced T cell activation in vivo. Forced expression of CIS also pro-
longs survival of CD4 T cells after TCR activation. Molecular events immediately downstream
from the TCR are not changed in CIS-expressing CD4 T cells, but activation of mitogen-acti-
vated protein (MAP) kinase pathways by TCR stimulation is significantly enhanced. Together
with the increased MAP kinase activation, a direct interaction of CIS and protein kinase C
 
u
 
 was
also demonstrated. These results suggest that CIS is one of the important regulators of TCR-
mediated T cell activation. The functions of CIS, enhancing TCR signaling and inhibiting cy-
tokine signaling, may be important in the regulation of immune response and homeostasis.
Key words: cytokine-induced SH2 protein • T cell receptor • signal transduction • 
mitogen-activated protein kinases • T cell activation
 
Introduction
 
The antigen engagement of TCRs initiates broad responses
required for proper immune function, including cell prolif-
eration, cytokine production, and apoptosis. TCR signal-
ing is initiated by the activation of cytosolic protein ty-
rosine kinases such as Lck, ZAP-70, and SYK, which
phosphorylate conserved motifs, immune receptor tyro-
sine-based activation motifs, within the cytoplasmic chains
of the invariant polypeptide complex of TCR (1, 2). The
phosphorylation of immune receptor tyrosine-based activa-
tion motifs recruits several signaling molecules and activates
various signal transduction pathways. Apart from the acti-
vation of cytoplasmic kinases, several adaptor proteins have
been shown to be involved in TCR signaling. These adap-
tor proteins lack enzymatic and transcriptional domains but
contain multiple motifs and domains that allow binding to
other proteins. Therefore, they are capable of integrating
the TCR signal into multiple downstream pathways (3, 4).
After the activation by TCR engagement, the ZAP-70/
SYK kinases phophorylate adaptor proteins such as linker
for activation of T cells (LAT)
 
1
 
 and Src homology 2 (SH2)
domain–containing leukocyte protein of 76 kD (SLP-76).
Phosphorylated LAT and SLP-76 directly bind to key pro-
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Abbreviations used in this paper:
 
 AP-1, activating protein 1; ATF, activating
transcription factor; CIS, cytokine-induced SH2 protein(s); ERK, extra-
cellular signal–regulated kinase; G3PDH, glyceraldehyde 3-phosphate de-
hydrogenase; GST, glutathione 
 
S
 
-transferase; JNK, c-Jun NH
 
2
 
-terminal
kinase; LAT, linker for activation of T cells; MAP, mitogen-activated
protein; MBP, myelin basic protein; PKC, protein kinase C; SEA, staph-
ylococcal enterotoxin A; SH2, Src homology 2; SLP-76, SH2 domain–
containing leukocyte protein of 76 kD; SOCS, suppressor of cytokine
signaling; STAT, signal transducer and activator of transcription. 
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teins such as phospholipase C
 
g
 
,
 
 
 
protein kinase C (PKC),
and Grb2-Sos. The resulting Ras activation leads to activa-
tion of mitogen-activated protein (MAP) kinase pathways
and subsequently the activation of transcription factors, in-
cluding activating protein 1 (AP-1), nuclear factor 
 
k
 
B, and
nuclear factor of activated T cells (3, 4).
Recently, a new adaptor protein family has been identi-
fied based on their structural similarities exhibiting an
NH
 
2
 
-terminal region of variable length, a highly variable
amino acid sequence, a central SH2 domain, and a striking
region of COOH-terminal homology, designated as the
suppressors of cytokine signaling (SOCS) box (5–8). Four
members (cytokine-induced SH2 protein [CIS], Jak bind-
ing protein [JAB]/SOCS1/STAT-induced STAT inhibitor
[SSI], SOCS2, and SOCS3) of this family were found to
negatively regulate cytokine signal transduction via the in-
teraction with phosphorylated cytoplasmic domains of cy-
tokine receptors (5), with activated Jak kinases (7), or with
signal transducer and activator of transcription (STAT) pro-
teins (9). Forced expression of CIS in a myloid cell line,
M1, could partially suppress IL-3–induced proliferation (5),
and negatively modulated the activation of STAT5 (9).
More recently, suppression of STAT5 functions in liver,
mammary glands, and T cells in CIS transgenic mice, was
also discovered (10). However, the involvement of SOCS
family proteins in other signaling pathways is unknown.
We report in this study that CIS expression is induced in T
cells by TCR stimulation. CD4 T cells from CIS trans-
genic mice, which express the transgene in the CD4 T cell
lineage, exhibited enhanced proliferative responses upon
TCR stimulation, and prolonged survival of activated T
cells. The increased responses in CIS-expressing CD4 T
cells are correlated with a significantly increased activation
of MAP kinases after TCR stimulation, suggesting that CIS
regulates the MAP kinase activation after TCR activation.
 
Materials and Methods
 
Differential Display.
 
 
 
Purified CD4 spleen T cells (5 
 
3
 
 10
 
6
 
)
were stimulated for 6 h with or without plate-bound anti-CD3
antibody (2C11, 10 
 
m
 
g/ml; PharMingen). After stimulation,
poly-A RNA was purified and submitted to differential display
analysis as described (11) using the Delta Differential Display kit
(Clontech). Putative differentially expressed cDNA fragments
were excised from dried sequencing gels, eluted in Tris-EDTA
(TE) buffer, and reamplified using the same primer pair originally
used in differential display. The differential expression of isolated
fragments was confirmed by Northern blot analysis. PCR prod-
ucts from confirmed fragments were cloned into a TA cloning
vector (Invitrogen), and sequenced.
 
Reverse Transcriptase PCR.
 
 
 
CD4 T cells from mouse spleen
were stimulated with anti-CD3. Total RNA was extracted with
Trizol solution (GIBCO BRL), reverse transcribed with a first
strand cDNA synthesis kit (Amersham Pharmacia Biotech) using
oligo-T primer, and amplified for expression of CIS, SOCS1,
SOCS2, SOCS3, SOCS5, and IL-2. Primer pairs for amplification
were: 5
 
9
 
-ACATGGTCCTCTGCGTACA-3
 
9
 
 and 5
 
9
 
-CAG-
CTGTCACATGCATGC-3
 
9
 
 for CIS; 5
 
9
 
-CGCCAACGGAA-
CTGCTTCTTC-3
 
9
 
 and 5
 
9
 
-TCAGGTAGTCACGGAGTACC-
3
 
9
 
 for SOCS1; 5
 
9
 
-TATATCCGTTAAGACGTCAGC-3
 
9
 
 and
5
 
9
 
-CTTGTTGGTAAAGGCAGTCC-3
 
9
 
 for SOCS2; 5
 
9
 
-TGT-
GTACTCAAGCTGGTGCAC-3
 
9
 
 and 5
 
9
 
-CATACTGATCCA-
GGAACTCC-3
 
9
 
 for SOCS3; and 5
 
9
 
-ATAAGTGGAGATGGT-
TCTGC-3
 
9
 
 and 5
 
9
 
-TCCTCCTGTGCAGAGTCC-3
 
9
 
 for SOCS5.
The primers specific for glyceraldehyde 3-phosphate dehydroge-
nase (G3PDH) confirmed that equal amounts of RNA were
present in each sample.
 
Transgenic Mice.
 
 
 
A murine full-length CIS cDNA was iso-
lated from a mouse liver cDNA library (Stratagene), as described
(12). The CIS cDNA in pBlueScript was excised and cloned into
the SalI site of plasmid CD4 promoter vector p428 (a gift from
N. Killeen, University of California, San Francisco). The vector-
free CD4-CIS fragment was excised by NotI from the sense-ori-
ented clone and used for construction of transgenic mice by
injection of the linearized promoter transgene cassette (free of
plasmid DNA) into the pronuclei of fertilized oocytes. Since the
silencer of CD4 regulatory elements has been deleted, the CIS
transgene is expressed in all T cells (13). All animals used in this
study were 4–6 wk old. Normal and CIS transgenic mice of the
same age were used in each experiment. T cell activation with
SEA was by intraperitoneal injection of 10 
 
m
 
g of staphylococcal
enterotoxin A (SEA) dissolved in saline as described (14).
 
Cell Proliferation Assay.
 
 
 
CD4 T cells were isolated from
spleen cells by anti-CD4–coated magnetic beads (Dynabeads
L3T4; Dynal). After each separation, the efficiency of CD4 cell
purification was analyzed by flow cytometry and was routinely
 
.
 
95%. Cells at 10
 
5
 
/well were cultured in 2 
 
m
 
g/ml anti-CD3, or
as indicated, 2C11 (PharMingen), precoated plates, or anti-CD3
plus 4 
 
m
 
g/ml anti-CD28 (PharMingen) or 2 
 
m
 
g/ml Con A
(PharMingen). The same amount of CD4 T cells were also cul-
tured with PMA and ionomycin (40 ng/ml each; Sigma Chemi-
cal Co.). The proliferative response to IL-2 was analyzed under
the condition that CD4 T cells were first stimulated with 5 
 
m
 
g/
ml anti-CD3 for 48 h and then washed and recounted before ad-
dition of 100 U/ml IL-2 (R&D Systems). The cells were used for
analysis at day 3 or as indicated in the figures after an 8-h pulse
with 1 
 
m
 
Ci/well [
 
3
 
H]thymidine. The incorporation of [
 
3
 
H]thy-
midine was measured with a 
 
b
 
-counter.
 
ELISA and Flow Cytometry.
 
 
 
T cell culture supernatants were
assayed in triplicate for IL-2 and IFN-
 
g
 
 by ELISA (PharMingen).
The FITC-labeled mAbs anti-CD3, anti-CD4, as well as the PE-
labeled anti-CD8 were purchased from PharMingen. Unsepa-
rated spleen or thymus cells were stained for 30 min at 4°C,
washed, and analyzed on a Becton Dickinson FACScan™ flow
cytometer.
 
Immunoprecipitation and Immunoblot Analysis.
 
 
 
Cell lysates of
anti-CD3–stimulated CD4 T cells were prepared in 1% NP-40
lysis buffer with protease inhibitors (Boehringer Mannheim) and
sodium vanadate, and immunoprecipitated with anti–ZAP-70
(Santa Cruz Biotechnology) or anti-CIS (Santa Cruz Biotechnol-
ogy). Immune complexes were resolved by 10% SDS-PAGE and
immunoblotted with antiphosphotyrosine (4G10; Upstate Bio-
technology, Inc.) for detection of phospho–ZAP-70 or with anti-
PKC
 
u
 
 (Santa Cruz Biotechnology) for detection of coprecipi-
tated PKC
 
u
 
. For confirming the expression of the CIS transgene,
CD4 T cells from CIS transgenic mice were lysed and blotted by
anti-CIS antiserum.
 
In Vitro Kinase Assay.
 
c-Jun NH
 
2
 
-terminal kinase (JNK) and
extracellular signal–regulated kinase (ERK) from cell lysates of
anti-CD3 (2 
 
m
 
g/ml) stimulated CD4 T cells were
 
 
 
purified by
immunoprecipitation with anti-JNK (Santa Cruz Biotechnology)
or anti-ERK antibody (Santa Cruz Biotechnology). As described 
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previously (15), kinase activity of JNK and ERK was measured
by incubation of immunoprecipitated JNK or ERK with glu-
tathione 
 
S
 
-transferase (GST)-c-Jun or myelin basic protein
(MBP), respectively, in the presence of 10 
 
m
 
Ci [
 
g
 
-
 
32
 
P]ATP in ki-
nase buffer containing 20 mM Hepes (pH 7.0), 5 mM 2-ME, 10
mM MgCl
 
2
 
, 0.1 mg/ml BSA, 10 
 
m
 
M unlabeled ATP at 37
 
8
 
C for
20 min. The phosphorylated GST-c-Jun or MBP was analyzed
by SDS-PAGE. The counts from each band were quantitated by
PhosphorImager
 
®
 
 using the ImageQuant
 
®
 
 software (Molecular
Dynamics).
 
Results
 
CIS Is an Immediate Early Gene Induced by TCR Stimula-
tion in T Cells. 
 
In search for molecules involved in
TCR-stimulated T cell activation, poly(A)-selected RNA
from CD4 T cells with or without anti-CD3 stimulation
for 6 h, was displayed by arbitrarily primed PCR finger-
printing (differential display) as described previously (11).
Eight differentially displayed bands were revealed from
anti-CD3–stimulated CD4 T cells. PCR products were
purified from these bands, reamplified, and sequenced. One
of these was CIS (Fig. 1 a, lanes 1 and 2), indicated by its
identical nucleotide sequence to the 3
 
9
 
 portion of the
cDNA encoding CIS protein (5). To confirm the induc-
tion of CIS expression by TCR stimulation, naive T cells
were incubated with or without anti-CD3 for different pe-
riods of time, and then total RNA was isolated and ana-
lyzed for CIS expression by Northern blot. CIS RNA was
not expressed in naive CD4 T cells, but was induced after
30 min stimulation with anti-CD3 (Fig. 1 b). Immunohis-
tochemical analysis demonstrated that CIS protein was de-
tected exclusively in activated T blast cells after anti-CD3
stimulation (Fig. 1 c). For investigation of the dependence
of CIS expression on TCR signaling in TCR-activated T
cells, expression of CIS was examined in the TCR-acti-
vated T cells after removal of anti-CD3 for 16 h. The ex-
pression of CIS was barely detected either at the protein or
RNA levels after withdrawal of anti-CD3 stimulation (Fig.
1, b and c), suggesting that TCR signaling regulates CIS
expression transcriptionally.
Since CIS can be induced by various cytokines, such as
IL-2, IL-3, and erythropoietin (EPO; 5, 9), the expression
of CIS in TCR-activated T cells could result from endoge-
nously produced IL-2. To address this possibility, RNA
extracted from CD4 T cells stimulated by anti-CD3 for
different periods of time was analyzed for IL-2 expression
by reverse transcription (RT)-PCR. In contrast to the early
induction of CIS expression, IL-2 was detected only after
anti-CD3 stimulation for 
 
.
 
1 h (Fig. 1 d), which is well
correlated with the results from mice with a fluorescent
marker for IL-2 gene activation (16). In addition, CIS ex-
pression at a late time point of anti-CD3 stimulation in the
Figure 1. CIS was induced by TCR acti-
vation. (a) Differentially displayed CIS tran-
script in anti-CD3–stimulated CD4 T cells.
(b) Northern analysis of mRNA from CD4
T cells treated with anti-CD3 for different
periods of time showing induced expression
of CIS (lanes 1–4), and dependence on
TCR activation (lane 5). The effect of
cycloheximide or cyclosporin A on anti-
CD3–induced CIS expression was ana-
lyzed by incubation with cyclosporin A
together with anti-CD3 or addition of cyclo-
heximide after anti-CD2 stimulation for 6 h
(lanes 6–8). Probe specific for G3PDH con-
firmed that equal amounts of RNA were
present in each sample. (c) The expression
of CIS in CD4 T cells was analyzed by
immunostaining with anti-CIS antibody
(Santa Cruz Biotechnology) as described
(reference 41). Induced CIS expression was
detected in activated T blasts after 20-h
stimulation with anti-CD3. Expressed CIS
was degraded in 16 h after withdrawal of
anti-CD3. (d) RT-PCR analysis of mRNA
from CD4 T cells activated with anti-CD3
for different periods of time showing the
kinetics of CIS, SOCS2, and IL-2 induc-
tion. Primers specific for G3PDH con-
firmed that equal amounts of RNA were
present in each sample. 
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presence of cycloheximide or cyclosporin A was examined
by Northern blotting. The amount of induced CIS mRNA
was not significantly altered by the protein synthesis inhibi-
tor, but was reduced by the treatment of cyclosporin A
(Fig. 1 b, lanes 6–8). This may indicate that in addition to
STAT5, a calcium-dependent pathway is also involved in
the regulation of CIS expression. Taken together, these re-
sults suggest that the immediate induction of CIS expres-
sion after TCR stimulation is transcriptionally regulated by
TCR signaling, but not by autocrine IL-2.
 
Selective Expression of SOCS Family Members in TCR-acti-
vated T Cells.
 
 
 
The SOCS protein family consists of at
least eight members (CIS, SOCS1–7; references 5–8, 17).
To determine whether other members of the SOCS pro-
tein family apart from CIS are also induced in TCR-acti-
vated T cells, resting CD4 T cells were stimulated with
anti-CD3 for different periods of time. After TCR stimula-
tion, RNA was extracted and analyzed by RT-PCR for
the expression of the four close homologues of CIS,
SOCS1, SOCS2, SOCS3, and SOCS5 (16). Selective ex-
pression of certain SOCS family members was revealed.
Similar to CIS, SOCS2 was a TCR-induced immediate
early gene indicative of a potential overlapping function
with CIS in TCR signaling (Fig. 1 d). SOCS1, SOCS3,
and SOCS5 were not induced by TCR stimulation (data
not shown), suggestive of distinct functions of SOCS pro-
teins in activated T cells.
 
Expression of CIS in CD4 T Cells of CD4-CIS Transgenic
Mice Promotes TCR-mediated T Cell Activation.
 
 
 
To assess
the physiological role of CIS protein in T cell function, we
generated CIS transgenic mice in which CIS expression
was driven by a CD4 promoter (13). After constructing the
transgenic construct, we sequenced the CD4 promoter as
well as CIS cDNA. The sequence was identical to the pub-
lished sequence (5). The expression of the CIS transgene in
CD4 T cells was verified by RT-PCR with one primer
from the construct-derived CD4 sequence and the other
primer derived from the CIS cDNA (Fig. 2 a), and by
Western blotting with anti-CIS antiserum (Fig. 2 b). The
molecular mass of transgenic CIS corresponded well to
previously published results (5). Of the three transgenic
lines used in this study, the level of transgene expression
was highest in line 3, intermediate in line 8, and low in line
12. Expression of the CIS transgene in CD4 T cells was
also directly detected by immunohistochemistry with anti-
CIS antiserum (Fig. 2 c). Expression of the CIS transgene
modestly reduced the number of thymocytes, but did not
alter the normal profiles of thymocyte subpopulations (data
not shown). The size and subset proportions of the periph-
eral T cell pool were unaffected. LNs were normal in size,
the number of splenic T cells was not significantly in-
creased, and the ratio of CD4 to CD8 cells was normal
(Fig. 2 d).
As it has been found that CIS negatively regulates cyto-
kine receptor signaling, we anticipated that CIS expression
in T cells would inhibit T cell activation mediated by
TCR. To examine the functionality of CD4 T cells from
CIS transgenic mice, responses to TCR stimulation were
analyzed by incubation of purified CD4 T cells with anti-
CD3 antibody. In contrast to the inhibitory effect of CIS in
cytokine-induced activation, CD4 T cells from spleens of
CIS transgenic mice expressed remarkably enhanced prolif-
erative responses to anti-CD3 stimulation (Fig. 3 a). CD4
T cells from spleens of normal mice exhibited only minor
proliferative responses towards the anti-CD3 stimulation
(Fig. 3 a). In agreement with previous reports (18), costim-
ulation of normal CD4 T cells with anti-CD28 in addition
to anti-CD3 induced pronounced proliferation (Fig. 3 a).
Moreover, this type of costimulated response was signifi-
cantly stronger in CD4 T cells expressing the CIS transgene
than in CD4 T cells from normal mice (Fig. 3 a). A
strongly enhanced proliferative response to PMA plus ion-
omycin stimulation was also detected in CD4 T cells from
CIS transgenic mice compared with CD4 T cells from nor-
mal mice (Fig. 3 a). To exclude the effect of IL-2 produced
by activated T cells, the proliferative response to anti-CD3
stimulation was also measured in the presence of anti–IL-2
antibodies. The antibodies did not affect the increased pro-
liferative response of CIS-expressing CD4 T cells to TCR
stimulation (Fig. 3 a). Previously, it was reported that the
IL-2–stimulated proliferative response was reduced slightly
in T cells expressing CIS (10). In this study, a very small
decrease of the proliferative response to 100 U/ml IL-2
was observed, which may be due to a partial inhibition of
STAT5 activated described below. These results suggested
Figure 2. Expression of CIS transgene in CD4 T cells in CIS trangenic
mice. (a) RT-PCR and (b) Western blot analysis of the CIS transgene ex-
pression in CD4 T cells showing expression of CIS transgene in three dif-
ferent transgenic lines. (c) Immunostaining of CD4 T cells with anti-CIS
antibody showing expression of CIS transgene. (d) FACS® analysis of
spleen cells showing normal profiles of T cell subpopulations. 
989
 
Li et al.
 
that CIS might be directly involved in TCR signaling.
Moreover, when stimulated with anti-CD3, CD4 T cells
expressing the CIS transgene secreted twice the amount of
IL-2 and IFN-
 
g
 
 compared with CD4 T cells of normal
mice (Fig. 3 b), further strengthening the evidence of in-
creased activation of CD4 T cells from CIS transgenic
mice.
 
CIS Prolongs Survival of CD4 T Cells After TCR Activa-
tion.
 
 
 
In addition to an enhanced proliferative T cell re-
sponse to TCR stimulation in vitro, anti-CD3–activated
CD4 T cells from CIS transgenic mice also survived longer
after stimulation than did CD4 T cells from normal mice
(Fig. 4 a). To further confirm the viability of activated
CD4 cells, CD4 cells from spleens of CIS transgenic and
normal mice were first stimulated with anti-CD3 for 3 d,
then the anti-CD3 was removed on day 4. After removal
of anti-CD3, cells were maintained in normal medium for
7 d. On day 10, cells were restimulated with anti-CD3.
The proliferation of CD4 cells was measured at different
time points after stimulation (Fig. 4 b). Significantly, after
removal of the anti-CD3 stimulus, the CIS-expressing
CD4 T cells, but not CD4 T cells from normal mice, could
be readily reactivated by TCR stimulation after 7 d (Fig. 4
b). These results suggest that CIS homeostatically regulates
the activated T cells by decreasing TCR-driven apoptosis.
 
CIS Expression Enhances T Cell Responses to Antigen In
Vivo. 
 
To test whether the augmented response to TCR ac-
tivation in vitro translated into an enhanced T cell response
to antigen in vivo, we stimulated CIS transgenic mice with
the superantigen SEA. A superantigen–MHC complex is
recognized by particular TCR V
 
b
 
 elements regardless of
their TCR-
 
a
 
 partner (14); therefore, they can be used to
measure a specific T cell proliferative response to antigen.
SEA activates T cells expressing TCR V
 
b
 
3 (14). Splenic
CD4 T cells bearing V
 
b
 
3 were quantified over a period of
2 wk. In both normal and CIS transgenic mice, the re-
sponse of CD4 TCR V
 
b
 
3 cells peaked on days 2–3. How-
ever, the expansion of V
 
b
 
3 cells was about twofold higher
in the CIS transgenic mice on day 3 (Fig. 5). The peak re-
sponse in normal mice dropped rapidly and was back to
basal level by day 7 (Fig. 5), due to apoptotic death of acti-
vated T cells (14). The CD4 TCR V
 
b
 
3 cells in the trans-
genic mice declined slowly, remaining in excess for 2 wk
after immunization (Fig. 5). These results indicate a func-
tional role of CIS in the regulation and maintenance of the
immune response to antigen in vivo.
 
CIS Regulates MAP Kinase Activation in T Cells after TCR
Stimulation.
 
 
 
Seeking the molecular mechanisms of CIS
function in TCR signaling, both proximal and later events
downstream of TCR signaling were analyzed in CIS trans-
genic CD4 T cells. The most proximal consequences of
TCR activation, as indicated by phosphorylation of ZAP-
70, were similar in normal and CIS transgenic CD4 T cells
(Fig. 6 a). In contrast, more downstream events such as the
activation of MAP kinases ERK and JNK were signifi-
cantly increased upon anti-CD3 stimulation in CIS trans-
genic T cells (Fig. 6 b). The peak of JNK and ERK activa-
tion was at 10 min in both wild-type and CIS transgenic T
Figure 3. Elevated CIS expression promoted T cell prolif-
eration and cytokine production. (a) Proliferation assay of
CD4 T cells was performed after 3-d stimulation with indi-
cated stimulators showing increased responses of CD4 T cells
from CIS transgenic mice. (b) ELISA of IL-2 and IFN-g (as-
say kit; PharMingen), showing increased expression of IL-2
and IFN-g in the CD4 T cells from CIS transgenic mice after
anti-CD3 stimulation for 3 d compared with normal mice.
Figure 4. Prolonged survival of TCR-activated T
cells from CIS transgenic mice. (a) TCR-mediated cell
death. Concentrations of viable cells were determined
in a hemocytometer, and viability was judged by try-
pan blue exclusion. (b) Reactivation of surviving CD4
T cells after withdrawal of the stimulator, anti-CD3,
showing that CIS expression could increase activation
and prolong survival of T cell in the absence of stimu-
lator. Anti-CD3 stimulation is indicated by black bars. 
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cells. However, according to mean PhosphorImage
 
®
 
 values
of phosphorylated c-Jun or MBP, the level of JNK activity
was increased more than sevenfold in CIS transgenic T cells
after 10 min stimulation (Fig. 6 c). Similarly to JNK, ERK
activity was increased in CIS transgenic T cells, but only
about threefold (Fig. 6 c). These results indicate that induc-
 
tion of MAP kinase activation is the mechanism by which
CIS regulates TCR activation.
 
CIS Interacts with PKC
 
u
 
 in the Activated T Cells from Nor-
mal Mice. To further understand the mechanisms of CIS
function in T cell activation, coprecipitation experiments
using anti-CIS antiserum were performed with normal
CD4 T cells stimulated with anti-CD3 for 16 h. In acti-
vated CD4 T cells, a coprecipitated protein with a molecu-
lar mass of 80 kD was obtained (Fig. 7 a). The copre-
cipitated species was PKCu confirmed by blotting of
coprecipitates with anti-PKCu antibody (Fig. 7 a). Since
PKCu is predominantly expressed in T cells and has the
ability to stimulate AP-1 transcriptional activity by regulat-
ing JNK (19), the association of CIS with PKCu may be
important for regulation of the PKCu activation of T cells.
CIS was mostly studied in its role as a negative regulator of
cytokine signaling, especially via the STAT5 pathway (10,
20). Therefore, we analyzed STAT5 activation in normal
and CIS-expressing CD4 T cells after anti-CD3 or IL-2 ac-
tivation. STAT5 phosphorylation was not detected in anti-
CD3–stimulated T cells either normal or CIS-expressing
(Fig. 7 b). The IL-2–induced STAT5 activation was ana-
lyzed by stimulation of anti-CD3 preactivated T cells with
100 U/ml IL-2. Although the phosphorylation of STAT5
Figure 5. CIS-expressing Vb3
CD4 T cells exhibited increased re-
sponsiveness to antigen in vivo.
Vb3-CD4 T cell responses to SEA
were analyzed by FACS® after stim-
ulation of mice with SEA (10 mg/ml
intraperitoneally), showing increased
and prolonged proliferative T cell
response in CIS transgenic mice.
Figure 6. CIS induced strong MAP ki-
nase activity. (a) Tyrosine phophorylation
assay of ZAP-70 in response to TCR stimu-
lation showed similar activation of ZAP-70
in CD4 T cells from normal and CIS trans-
genic mice. (b) Kinase assays of JNK and
ERK from anti-CD3–activated CD4 T cells
showing increased JNK and ERK activation
in CIS transgenic CD4 T cells. The results
were representative of three experiments
with similar results. (c) Augmentation of the
activity was calculated as the ratio between
the mean PhosphorImage® values of stimu-
lated samples and the mean values from un-
stimulated samples.991 Li et al.
was detected in both normal and CIS-expressing T cells,
the level of STAT5 phosphorylation in CIS-expressing T
cells was slightly decreased (Fig. 7 b). This partial inhibition
of STAT5 phosphorylation in CIS-expressing T cells is
consistent with a previous report (20). Thus, the function
of CIS association with PKCu may be distinct from the in-
hibitory effect of CIS on STAT5 activation, and may be
important in regulation of TCR signaling.
Discussion
Members of the SOCS protein family were discovered as
negative regulators of cytokine signaling by inhibition of
the Jak-STAT pathway (5–8). CIS is the first discovered
SOCS protein and an immediate early gene induced by IL-2,
IL-3, and EPO (5, 9). CIS was demonstrated to act as a
negative feedback loop for inhibition of IL-3– and EPO-
activated Jak-STAT5 signaling by blocking the interaction
of STAT5 and its docking sites on the cytoplasmic domain
of the receptor chain (5). Forced expression of CIS inhib-
ited IL-3–induced proliferation of M1 cells and inhibited
EPO-dependent tyrosine phophorylation of STAT5 (9).
The function of CIS in other signaling pathways is un-
known.
By differential display analysis of TCR-induced tran-
scripts in T cells, we found that CIS is a TCR-induced im-
mediate early gene. The expression of CIS in activated T
cells was dependent on the presence of TCR stimulation,
suggestive of an important role for CIS in the TCR signal-
ing. This was demonstrated by a functional study of CIS-
expressing T cells from CIS transgenic mice. In contrast to
the inhibitory effect in IL-3 and EPO signaling, expression
of CIS strongly promoted T cell proliferation, cytokine
production, and prolonged survival of activated T cells.
The regulation of TCR signaling correlates with the CIS-
mediated activation of MAP kinases, indicated by the inter-
action of CIS with PKCu in TCR-stimulated normal CD4
T cells as well as the significantly increased JNK and ERK
activities in the CIS-expressing T cells after TCR stimula-
tion.
Analysis of SOCS protein expression in TCR-stimulated
T cells revealed selective induction of CIS and SOCS2
proteins, indicative of specificity of CIS in regulation of
TCR signaling and the potential overlapping of function
between CIS and SOCS2. The selective induction of
SOCS family proteins by cytokines has also been observed.
Thus, CIS and SOCS1, but not SOCS2 or SOCS3, were
induced by IL-6 in the M1 cell line (6). These results to-
gether with ours suggest that despite the structural similar-
ity among SOCS proteins, they selectively participate in
different signaling pathways.
CIS is one of the STAT5-regulated genes. Results from
STAT5a/b mutant mice showed that the expression of CIS
in the thymus was dependent on the STAT5 proteins (21).
Furthermore, two STAT5 binding sites were discovered
within the CIS gene promoter (22). Therefore, CIS has
been proposed to be a feedback modulator of STAT5. Its
expression is induced by STAT5 and it negatively modu-
lates STAT5 activation. Interestingly, it was found that ac-
tivated STAT5 interacts with the TCR complex and stim-
ulates T cell proliferation (23). However, this was the
reverse of the recent findings, in which the activation of
STAT5 specifically does not occur through the TCR sig-
naling (24). We could not detect the STAT5 activation af-
ter TCR stimulation in T cells isolated from spleen of nor-
mal or CIS transgenic mice. This may be due to the
difference of primary cells used in this study and cell lines
used in the previous report (23). Even if STAT5 activation
is induced after TCR stimulation, the strong enhancement
of the proliferative response to TCR stimulation in CIS-
expressing T cells suggested that the function of CIS in T
cell activation may not associate with STAT5. Suppression
of STAT5 functions by CIS was also shown by the study of
the CIS transgenic mice under the control of a b-actin pro-
moter (10). From that study, in addition to the inhibition
of STAT5 activation in liver and mammary glands by the
expression of CIS transgene, it inhibited IL-2–induced
STAT5 activation in T cells (10). Moreover, consistent
with our finding, anti-CD3 plus anti-CD28 was shown to
induce CIS and TCR stimulation of CIS transgenic T cells,
resulting in an augmented, rather than decreased, IL-2Ra
expression (10). Given these results, the authors suggested
that CIS might be involved in TCR signaling in a STAT5-
independent manner (10). Interestingly, in b-actin pro-
Figure 7. CIS interacts with activated PKCu in activated normal T
cells, and expression of CIS slightly modulates IL-2–induced STAT5 acti-
vation in activated T cells. (a) CD4 T cells from spleen of normal mice
were incubated without (lane 1) or with anti-CD3 (lane 2) for 16 h. The
activated CD4 T cells were lysed, and cleared lysates were precipitated
with anti-CIS antiserum. The precipitates were separated on 10% SDS-
PAGE and sequentially blotted by anti-PKCu and anti-CIS antibodies,
respectively. (b) The activation of STAT5 was directly analyzed in CD4
T cells after 15 min incubation with 5 mg/ml anti-CD3 and in CD4 T
cells that were prestimulated for 48 h with 5 mg/ml anti-CD3 and then
incubated for 15 min with 200 U/ml IL-2. The STAT5 was precipitated
with anti-STAT5 antiserum and blotted by an antibody specific for phos-
phorylated STAT5. Western blot with anti-STAT5 antiserum showed
similar amounts of STAT5 in all samples tested.992 CIS Regulates T Cell Activation
moter–driven CIS transgenic mice, the inhibition of
STAT5 activation by the CIS transgene did not signifi-
cantly affect the proliferation of T cells towards the IL-2
stimulation (10). This does not correlate with the findings
from STAT5 knockout mice, in which the cell cycle pro-
gression of T cells induced by both anti-CD3 and IL-2 was
completely abolished (21). Conflicting results with regard
to inhibition of STAT5 activation by CIS were reported
with a CIS-transfected T cell line (25). It was found that
IL-2–induced tyrosine phosphorylation of STAT5b was
markedly reduced in a T cell line expressing SOCS3 but
not CIS (25). In our CIS trasgenic mice, the STAT5 acti-
vation after IL-2 stimulation was only partially inhibited by
the expression of CIS transgene. We also found that the IL-
2–induced proliferation of CIS-expressing T cells was not
significantly altered. The systemic expression of CIS from
b-actin promoter–driven transgenics may result in the de-
velopmental deficiency of certain Jak kinase function that
may be required for STAT5 activation. This may not be
the case in lineage-specific transgenics. Nevertheless, the
positive regulation of TCR signaling and negative regula-
tion of IL-2–induced STAT5 activation indicate a recipro-
cal function of CIS dependent on distinct stimuli.
In search for the mechanisms of CIS function in TCR
signaling, we have examined proximal as well as down-
stream events of TCR signaling in CIS-expressing T cells
after TCR stimulation. We could not detect the interac-
tion of CIS with the TCR complex, ZAP-70, and Lck
(data not shown). The activation of ZAP-70 after TCR
stimulation was similar in normal and CIS-expressing T
cells, indicating that CIS regulates downstream events of
TCR signaling. Indeed, after TCR stimulation, a binding
of CIS to PKCu in normal T cells and a strong increase of
MAP kinase activity in CIS-expressing T cells were dem-
onstrated. Furthermore, the JNK activity was remarkably
induced in CIS-expressing T cells and barely detected in
normal T cells after TCR stimulation. ERK activity was
also increased more than threefold in CIS-expressing T
cells. On the basis of these results, we suggest that CIS is
one of intermediate regulators that transmit a signal from
TCR to MAP kinase pathways by regulation of the PKCu.
PKCu is preferentially expressed in T cells and selec-
tively modulated during T cell activation (19, 26, 27). It
stimulates the transcription factor AP-1 in T cells by activa-
tion of MAP kinase (19, 26). The MAP kinases are essential
for TCR-mediated activation by regulation of the AP-1
transcription factor composed of Jun, Fos, and activating
transcription factor (ATF) subunits (28). Activated AP-1
regulates different target genes and thus executes distinct
functions of activated T cells (24). Both ERK and JNK ac-
tivation are required for T cell activation (28, 29). How-
ever, while ligation of the TCR–CD3 complex activates
ERK (30), the activation of JNK requires the occupation of
both the TCR and CD28 (31), resulting in optimal activa-
tion of T cells. The greatly enhanced JNK activation in
CIS-expressing T cells may indicate an important role of
CIS in the integration of TCR and CD28 signals. Interest-
ingly, induction of functional inactivation or anergy in T
cells correlates with the lack of ERK and JNK activation
(32). After TCR activation, kinase cascades, regulated by
multiple factors, activate the MAP kinases (28). Although
several of these regulators have been identified, including
the guanine nucleotide binding proteins p21ras, PKC (29),
and also the Rho family GTPases, which activate the JNK
(33), it is still largely unknown how the initial events after
TCR activation regulate the activation of MAP kinase
pathways. Several adapter proteins like Shc, Grb2, and
SLP-76 have been shown to be involved in the regulation
of MAP kinase activity (4). Grb2 was found to associate
with LAT after phosphorylation of LAT by ZAP-70. Re-
cruitment of Grb2 to LAT localizes Sos protein to Ras, re-
sulting in Ras activation and subsequently activation of
MAP kinase pathways (4). In parallel with the Grb protein
family, the functions of the SOCS family proteins are also
mediated by interaction of the SH2 domain of SOCS pro-
teins to target molecules (3).
The different functions of CIS in different signaling
pathways may largely depend on the target proteins in CIS-
expressing cells. The association of CIS with PKCu and in-
creased MAP kinase activity in CIS transgenic T cells after
TCR stimulation indicate that the function of CIS in regu-
lation of the T cell activation may be distinct from its in-
hibitory effect for cytokine signaling.
Our data provide functional and biochemical evidence
for CIS regulation of T cell activation. The SOCS protein
family has been identified on the basis of its negative modu-
lation of cytokine signaling. Germline mutation of the
SOCS1 gene resulted in growth retardation and death
within 3 wk after birth (34, 35). Multiple organ apoptosis in-
cluding in lymphocytes was observed in SOCS1-deficient
mice (36), which was due to the inhibition of fatal neonatal
actions of IFN-g (36, 37). More recently, the negative regu-
lation of fetal liver hematopoiesis was discovered from the
study of SOCS3-deficient mice (38) indicating that SOCS
proteins have more diverse functions than as an inhibitor of
cytokine signaling. Indeed, rapid induction of SOCS3 by
growth hormone (39) and inhibition of Tec tyrosine kinase
by SOCS1 have been demonstrated (40), suggesting that
SOCS proteins exhibit broad functions across multiple sig-
naling pathways. The presented results clearly show that the
function of CIS is not limited to negative regulation. The bi-
directional regulation of T cell activation and cytokine sig-
naling by CIS may represent a novel mechanism for control-
ling both immune responses and homeostasis.
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